Fig. 1

a Effect of decitabine (DEC) on tumor growth and survival in the absence or presence of donor lymphocyte infusion (DLI) in a post-transplantation early relapse mouse model. B6-derived bone marrow cells were transplanted to F1 mice after non-myeloablative conditioning, and DEC was injected following the inoculation of P815 cells. Survival and tumor size were assessed in the b, c absence or d, e presence of DLI. The experiment was conducted in 3 times.*P < 0.05, **P < 0.01, ***P < 0.001 for control vs. DEC-treated group